

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 24, 2003

BECTON, DICKINSON AND COMPANY

(Exact name of registrant as specified in its charter)

<TABLE>

<S>	New Jersey	<C> 001-4802	<C> 22-0760120
	(State or other juris- diction of incorporation)	(Commission File Number)	(IRS Employer Iden- tification Number)
	1 Becton Drive, Franklin Lakes, New Jersey		07417-1880
	(Address of principal executive offices)		(Zip Code)

</TABLE>

Registrant's telephone number, including area code (201) 847-6800

N/A

(Former name or former addresses if changed since last report.)

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit 99.1 Press release dated July 24, 2003
announcing the financial results for the third
quarter ended June 30, 2003.

Item 9. Regulation FD Disclosure.

The information contained in this Item 9 of this Current Report is being furnished pursuant to "Item 12. Results of Operations and Financial Condition", in accordance with SEC Release No. 33-8216. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

On July 24, 2003, the Company issued a press release announcing its results for the third quarter ended June 30, 2003. A copy of the press release is attached hereto as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Gary DeFazio

Gary DeFazio
Assistant Secretary

Date: July 24, 2003

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

Exhibit Number -----	Description of Exhibits -----
<S> 99.1	<C> Press release issued July 24, 2003

</TABLE>

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as.....'TM'

1 Becton Drive
Franklin Lakes, NJ 07417
Tel: 201.847.4000
Fax: 201.847.6692
www.bd.com

News Release

[Becton, Dickinson and Company LOGO]
Helping all people
live healthy lives

Contact:

Charles A. Borgognoni/Corporate Communications - 201-847-6651
Patricia A. Spinella/Investor Relations - 201-847-5453

BD ANNOUNCES RESULTS FOR FISCAL THIRD QUARTER

Franklin Lakes, NJ (July 24, 2003) - BD (Becton, Dickinson and Company) (NYSE:BDX) today reported record quarterly revenues of \$1.165 billion for the fiscal third quarter ended June 30, 2003, an increase of 17 percent from the same period a year ago. At constant foreign exchange rates, revenues increased 11 percent. Revenue growth in all segments benefited from favorable foreign currency translation, particularly with respect to the Euro.

Diluted earnings per share and net income for the quarter were 49 cents and \$130 million, respectively. Included in third quarter results were non-cash charges of \$34 million, recorded in cost of products sold, relating to the write-down of certain intangible assets and inventory in the BD Biosciences segment. These charges reduced net income by \$20 million and diluted earnings per share by 8 cents. For the third quarter of fiscal 2002, diluted earnings per share were 44 cents and net income was \$120 million, including special charges of \$12 million, or 4 cents per share relating to the manufacturing restructuring in the BD Medical Systems segment.

"Strong revenue growth in all three of our business segments, as well as in most of our international regions, was the driving force behind another sound quarter for BD," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "Of the many products that added to this quarter's revenue growth, we were especially pleased by the contribution from the BD FACSARIATM, our recently launched BD Biosciences instrument, which generated \$20 million in revenue."

Q3 Segment Results

In the BD Medical Systems segment, worldwide revenues of \$648 million increased 19 percent. The Medical Surgical, Pharmaceutical Systems and Consumer Healthcare units each contributed double-digit growth to the segment's results. Included in BD Medical Systems revenues were U.S. safety-engineered product sales of \$101 million, versus \$88 million in the prior year's quarter. The overall growth rate in the segment was offset in part by reduced sales of conventional devices in the U.S. due to the transition to safety-engineered devices.

In the BD Clinical Laboratory Solutions segment, worldwide revenues increased 13 percent to \$338 million. Revenue growth of 11 percent in the Preanalytical Solutions unit of the segment was attributable in part to U.S. safety-engineered device sales, which were \$66 million, versus \$57 million in the prior year's quarter. These results were offset in part by reduced sales of conventional devices due to the transition to safety-engineered devices. Worldwide revenues of the Diagnostic Systems unit of the segment increased 17 percent. This growth reflected strong worldwide sales of its molecular diagnostic platform, BD ProbeTecTM ET.

In the BD Biosciences segment, worldwide revenues grew 14 percent to \$179 million. Revenue growth was driven by strong sales of the new BD FACSARIATM cell sorter, which BD Biosciences began shipping at the end of March, and by sales of immunology/cell biology reagents. This growth was offset in part by continued weaker demand for certain molecular biology (Clontech) reagents.

Non-Cash Charges

During the third quarter, the BD Biosciences segment discontinued the development of certain products and product applications associated with its BD IMAGNTM instrument platform. In connection with this decision, the Company recorded an impairment charge of \$27 million for related intangible assets and inventory. In addition, as the result of a revised outlook with respect to under-performing portions of its molecular biology (Clontech) product line, BD Biosciences wrote down the value of related inventory and intellectual property by \$7 million. In connection with the foregoing decisions, in the third quarter, the Company recorded, in cost of products sold, non-cash charges of \$34 million.

Q3 Geographic Results

- -----

On a geographic basis, third quarter revenues in the U.S. increased 10 percent to \$583 million. Revenues outside the U.S. of \$582 million grew 24 percent, or 11 percent at constant foreign exchange rates. International revenues in the third quarter, benefited from favorable foreign exchange as well as strong performance in Europe, Canada, Japan, and Asia Pacific, offset in part by the effects of unfavorable performance and economic conditions in Latin America.

Nine-Month Results

- -----

For the nine-month period ended June 30, 2003, reported revenues were \$3.351 billion, a 13 percent increase over a year ago, or 9 percent at constant foreign exchange rates. Diluted earnings per share for the nine-month period were \$1.46, or \$1.54 excluding the aforementioned non-cash charges relating to intangible asset impairments and inventory write-downs. For the same period in fiscal 2002, diluted earnings per share were \$1.29, or \$1.35 before the special charges related to the manufacturing restructuring in the BD Medical Systems segment.

Fiscal 2003 Outlook

- -----

For the fourth quarter, the Company expects diluted earnings per share of 60 cents, and \$2.06 for the full fiscal year, or \$2.14 excluding the 8 cents of non-cash charges relating to the intangible asset impairments and inventory write-downs included in the third quarter results. These expectations assume that foreign currency exchange rates, in particular as related to the Euro, remain approximately at current levels.

Conference Call Information

- -----

A conference call regarding BD's third quarter results and its expectations for the fourth quarter will be broadcast live on BD's website www.bd.com/investors at 8:30 a.m. (ET) Thursday, July 24, 2003. The conference call will be available for replay on BD's website www.bd.com/investors or at 1-800-391-9851 (domestic) and 1-402-220-9825 (international) through the close of business on July 31, 2003.

This news release contains certain non-GAAP financial measures. A reconciliation of these measures to the comparable GAAP measures is included in this release and in the attached financial tables.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2002, BD reported total revenues of \$4.033 billion.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; BD's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

<TABLE>
<CAPTION>

	Three Months Ended June 30,		% Change
	2003	2002	
<S>	<C>	<C>	<C>
REVENUES	\$1,165,369	\$ 998,460	16.7
Cost of products sold	622,387 *	514,071	21.1
Selling and administrative	308,475	253,857	21.5
Research and development	60,042	53,037	13.2
Special charges	--	11,571	NM
TOTAL OPERATING COSTS AND EXPENSES	990,904	832,536	19.0
OPERATING INCOME	174,465	165,924	5.1
Interest expense, net	(9,658)	(8,678)	11.3
Other (expense) income, net	(2,036)	1,313	NM
INCOME BEFORE INCOME TAXES	162,771	158,559	2.7
Income tax provision	32,753	38,834	(15.7)
NET INCOME	\$ 130,018	\$ 119,725	8.6
EARNINGS PER SHARE			
Basic	\$ 0.51	\$ 0.46	10.9
Diluted	\$ 0.49	\$ 0.44	11.4
AVERAGE SHARES OUTSTANDING			
Basic	255,038	258,067	
Diluted	265,088	269,011	

</TABLE>

NM - Not Meaningful

* Includes \$34,231 of non-cash charges, as more fully described on the following page.

Page 1

BECTON DICKINSON AND COMPANY
RECONCILIATION TO PRO FORMA AMOUNTS
Three Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	2003		
	As Reported	Non-cash Charges*	Excluding Charges
<S>	<C>	<C>	<C>
Gross Profit	\$ 542,982	\$ 34,231	\$ 577,213
as a % of revenues	46.6%		49.5%
Operating Income	174,465	34,231	208,696
as a % of revenues	15.0%		17.9%
Net Income	130,018	20,196	150,214
as a % of revenues	11.2%		12.9%
Diluted EPS	0.49	0.08	0.57

</TABLE>

<TABLE>
<CAPTION>

	2002		
	As Reported	Special Charges**	Excluding Charges
<S>	<C>	<C>	<C>
Gross Profit	\$ 484,389	\$ --	\$ 484,389
as a % of revenues	48.5%		48.5%
Operating Income	165,924	11,571	177,495
as a % of revenues	16.6%		17.8%
Net Income	119,725	10,254	129,979
as a % of revenues	12.0%		13.0%
Diluted EPS	0.44	0.04	0.48

* Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

** Relates to the fiscal 2002 manufacturing restructuring in the BD Medical Systems segment.

Page 2

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Nine Months Ended June 30,		
	2003	2002	% Change
<S>	<C>	<C>	<C>
REVENUES	\$3,351,058	\$2,956,377	13.4
Cost of products sold	1,750,854 *	1,536,966	13.9
Selling and administrative	891,454	749,811	18.9
Research and development	179,921	164,588	9.3
Special charges	--	21,508	NM
TOTAL OPERATING COSTS AND EXPENSES	2,822,229	2,472,873	14.1
OPERATING INCOME	528,829	483,504	9.4
Interest expense, net	(26,944)	(27,088)	(0.5)
Other (expense) income, net	(3,799)	189	NM
INCOME BEFORE INCOME TAXES	498,086	456,605	9.1
Income tax provision	112,390	108,019	4.0
NET INCOME	\$ 385,696	\$ 348,586	10.6
EARNINGS PER SHARE			
Basic	\$ 1.51	\$ 1.34	12.7
Diluted	\$ 1.46	\$ 1.29	13.2
AVERAGE SHARES OUTSTANDING			
Basic	255,008	258,568	

</TABLE>

NM - Not Meaningful

* Includes \$34,231 of non-cash charges, as more fully described on the following page.

Page 3

BECTON DICKINSON AND COMPANY
RECONCILIATION TO PRO FORMA AMOUNTS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	2003		
	As Reported	Non-cash Charges*	Excluding Charges
<S>	<C>	<C>	<C>
Gross Profit	\$1,600,204	\$ 34,231	\$1,634,435
as a % of revenues	47.8%		48.8%
Operating Income	528,829	34,231	563,060
as a % of revenues	15.8%		16.8%
Net Income	385,696	20,196	405,892
as a % of revenues	11.5%		12.1%
Diluted EPS	1.46	0.08	1.54

<TABLE>
<CAPTION>

	2002		
	As Reported	Special Charges**	Excluding Charges
<S>	<C>	<C>	<C>
Gross Profit	\$1,419,411	\$ --	\$1,419,411
as a % of revenues	48.0%		48.0%
Operating Income	483,504	21,508	505,012
as a % of revenues	16.4%		17.1%
Net Income	348,586	16,692	365,278
as a % of revenues	11.8%		12.4%
Diluted EPS	1.29	0.06	1.35

* Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

** Relates to the fiscal 2002 manufacturing restructuring in the BD Medical Systems segment.

Page 4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

<S>	Three Months Ended June 30,		
	2003	2002	% Change
<C>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
United States	\$ 306,036	\$272,020	12.5
International	342,392	272,156	25.8
TOTAL	\$ 648,428	\$544,176	19.2
BD CLINICAL LABORATORY SOLUTIONS			
United States	\$ 190,888	\$174,976	9.1
International	147,295	123,054	19.7
TOTAL	\$ 338,183	\$298,030	13.5
BD BIOSCIENCES			
United States	\$ 86,164	\$ 81,653 *	5.5
International	92,594	74,601 *	24.1
TOTAL	\$ 178,758	\$156,254	14.4
TOTAL REVENUES			
United States	\$ 583,088	\$528,649 *	10.3
International	582,281	469,811 *	23.9
TOTAL	\$1,165,369	\$998,460	16.7

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

<S>	Nine Months Ended June 30,		
	2003	2002	% Change
<C>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
United States	\$ 895,256	\$ 791,995	13.0
International	926,628	785,595	18.0
TOTAL	\$1,821,884	\$1,577,590	15.5
BD CLINICAL LABORATORY SOLUTIONS			
United States	\$ 588,626	\$ 540,866	8.8
International	438,011	369,570	18.5
TOTAL	\$1,026,637	\$ 910,436	12.8
BD BIOSCIENCES			
United States	\$ 234,046	\$ 239,704 *	(2.4)
International	268,491	228,647 *	17.4
TOTAL	\$ 502,537	\$ 468,351	7.3
TOTAL REVENUES			
United States	\$1,717,928	\$1,572,565 *	9.2
International	1,633,130	1,383,812 *	18.0
TOTAL	\$3,351,058	\$2,956,377	13.4

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	2003	United States 2002	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
Medical Surgical	\$190,831	\$175,185 *	8.9
Consumer Health Care	81,329	70,122 *	16.0
Pharmaceutical Systems	28,029	19,909	40.8
Ophthalmic Systems	5,847	6,804	(14.1)
TOTAL	\$306,036	\$272,020	12.5
BD CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$102,869	\$ 97,306	5.7
Diagnostic Systems	88,019	77,670	13.3
TOTAL	\$190,888	\$174,976	9.1
BD BIOSCIENCES			
Discovery Labware	\$ 25,053	\$ 26,643	(6.0)
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	34,960	27,668	26.4
Molecular Biology Reagents	8,091	10,187 *	(20.6)
Immunology/Cell Biology Reagents	18,060	17,155	5.3
Total Immunocytometry & Reagents	61,111	55,010 *	11.1
TOTAL	\$ 86,164	\$ 81,653 *	5.5
TOTAL UNITED STATES	\$583,088	\$528,649 *	10.3

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

International

% Change

<S>	2003	2002	% Change		
	<C>	<C>	Reported	FX Neutral	FX Impact
BD MEDICAL SYSTEMS					
Medical Surgical	\$179,543	\$148,457	20.9	12.8	8.1
Consumer Health Care	55,785	45,361	23.0	10.5	12.5
Pharmaceutical Systems	99,319	71,210	39.5	17.5	22.0
Ophthalmic Systems	7,745	7,128	8.7	(5.4)	14.1
TOTAL	\$342,392	\$272,156	25.8	13.1	12.7
BD CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$ 77,503	\$ 65,551	18.2	5.8	12.4
Diagnostic Systems	69,792	57,503	21.4	9.0	12.4
TOTAL	\$147,295	\$123,054	19.7	7.3	12.4
BD BIOSCIENCES					
Discovery Labware	\$ 21,596	\$ 16,993	27.1	13.1	14.0
Immunocytometry & Reagents:					
Flow Cytometry Instruments & Reagents	49,121	38,659	27.1	11.2	15.9
Molecular Biology Reagents	7,720	8,021 *	(3.8)	(14.0)	10.2
Immunology/Cell Biology Reagents	14,157	10,928	29.5	13.7	15.8
Total Immunocytometry & Reagents	70,998	57,608 *	23.2	8.1	15.1
TOTAL	\$ 92,594	\$ 74,601 *	24.1	9.3	14.8
TOTAL INTERNATIONAL	\$582,281	\$469,811 *	23.9	11.0	12.9

* Prior year data reclassified to conform to current year presentation

Page 8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

<S>	Total		% Change		
	2003	2002	Reported	FX Neutral	FX Impact
BD MEDICAL SYSTEMS					
Medical Surgical	\$ 370,374	\$323,642 *	14.4	10.7	3.7
Consumer Health Care	137,114	115,483 *	18.7	13.8	4.9
Pharmaceutical Systems	127,348	91,119	39.8	22.6	17.2
Ophthalmic Systems	13,592	13,932	(2.4)	(9.6)	7.2
TOTAL	\$ 648,428	\$544,176	19.2	12.8	6.4
BD CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$ 180,372	\$162,857	10.8	5.8	5.0
Diagnostic Systems	157,811	135,173	16.7	11.5	5.2
TOTAL	\$ 338,183	\$298,030	13.5	8.4	5.1
BD BIOSCIENCES					
Discovery Labware	\$ 46,649	\$ 43,636	6.9	1.5	5.4
Immunocytometry & Reagents:					
Flow Cytometry Instruments & Reagents	84,081	66,327	26.8	17.5	9.3
Molecular Biology Reagents	15,811	18,208	(13.2)	(17.7)	4.5

Immunology/Cell Biology Reagents	32,217	28,083	14.7	8.6	6.1
Total Immunocytometry & Reagents	132,109	112,618	17.3	9.6	7.7
TOTAL	\$ 178,758	\$156,254	14.4	7.3	7.1
TOTAL REVENUES	\$1,165,369	\$998,460	16.7	10.6	6.1

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	United States		
	2003	2002	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
Medical Surgical	\$ 564,313	\$ 512,264 *	10.2
Consumer Health Care	240,483	209,337 *	14.9
Pharmaceutical Systems	72,351	50,827	42.3
Ophthalmic Systems	18,109	19,567	(7.5)
TOTAL	\$ 895,256	\$ 791,995	13.0
BD CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 306,850	\$ 277,118	10.7
Diagnostic Systems	281,776	263,748	6.8
TOTAL	\$ 588,626	\$ 540,866	8.8
BD BIOSCIENCES			
Discovery Labware	\$ 71,399	\$ 72,545	(1.6)
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	87,300	88,078	(0.9)
Molecular Biology Reagents	24,353	30,668 *	(20.6)
Immunology/Cell Biology Reagents	50,994	48,413	5.3
Total Immunocytometry & Reagents	162,647	167,159 *	(2.7)
TOTAL	\$ 234,046	\$ 239,704 *	(2.4)
TOTAL UNITED STATES	\$1,717,928	\$1,572,565 *	9.2

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 10

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

		International					
				% Change			
		2003	2002	Reported	FX Neutral	FX Impact	
<S>	<C>	<C>	<C>	<C>	<C>	<C>	
BD MEDICAL SYSTEMS							
Medical Surgical	\$	492,978	\$	438,598	12.4	6.8	5.6
Consumer Health Care		150,008		136,800	9.7	1.2	8.5
Pharmaceutical Systems		262,048		190,776	37.4	19.8	17.6
Ophthalmic Systems		21,594		19,421	11.2	(0.5)	11.7
TOTAL	\$	926,628	\$	785,595	18.0	8.8	9.2
BD CLINICAL LABORATORY SOLUTIONS							
Preanalytical Solutions	\$	216,782	\$	188,802	14.8	5.0	9.8
Diagnostic Systems		221,229		180,768	22.4	13.4	9.0
TOTAL	\$	438,011	\$	369,570	18.5	9.1	9.4
BD BIOSCIENCES							
Discovery Labware	\$	60,511	\$	49,566	22.1	11.3	10.8
Immunocytometry & Reagents:							
Flow Cytometry Instruments & Reagents		144,313		123,604	16.8	4.6	12.2
Molecular Biology Reagents		24,501		23,999 *	2.1	(6.8)	8.9
Immunology/Cell Biology Reagents		39,166		31,478	24.4	11.5	12.9
Total Immunocytometry & Reagents		207,980		179,081 *	16.1	4.3	11.8
TOTAL	\$	268,491	\$	228,647 *	17.4	5.8	11.6
TOTAL INTERNATIONAL	\$	1,633,130	\$	1,383,812 *	18.0	8.4	9.6

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 11

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

		Total					
				% Change			
		2003	2002	Reported	FX Neutral	FX Impact	
<S>	<C>	<C>	<C>	<C>	<C>	<C>	
BD MEDICAL SYSTEMS							
Medical Surgical	\$	1,057,291	\$	950,862 *	11.2	8.6	2.6
Consumer Health Care		390,491		346,137 *	12.8	9.5	3.3
Pharmaceutical Systems		334,399		241,603	38.4	24.5	13.9
Ophthalmic Systems		39,703		38,988	1.8	(4.0)	5.8
TOTAL	\$	1,821,884	\$	1,577,590	15.5	10.9	4.6
BD CLINICAL LABORATORY SOLUTIONS							
Preanalytical Solutions	\$	523,632	\$	465,920	12.4	8.4	4.0

Diagnostic Systems	503,005	444,516	13.2	9.5	3.7
TOTAL	\$1,026,637	\$ 910,436	12.8	8.9	3.9
BD BIOSCIENCES					
Discovery Labware	\$ 131,910	\$ 122,111	8.0	3.7	4.3
Immunocytometry & Reagents:					
Flow Cytometry Instruments & Reagents	231,613	211,682	9.4	2.3	7.1
Molecular Biology Reagents	48,854	54,667	(10.6)	(14.5)	3.9
Immunology/Cell Biology Reagents	90,160	79,891	12.9	7.8	5.1
Total Immunocytometry & Reagents	370,627	346,240	7.0	0.9	6.1
TOTAL	\$ 502,537	\$ 468,351	7.3	1.6	5.7
TOTAL REVENUES	\$3,351,058	\$2,956,377	13.4	8.8	4.6

</TABLE>

* Prior year data reclassified to conform to current year presentation